Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1781 - PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung.


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Tumour Immunology

Tumour Site

Neuroendocrine Neoplasms


diane damotte


Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269


D. damotte1, M.C. Charpentier2, M. Bernardi3, E. Watkin4, I. Goubin Versini5, R. Lamy6, N. Piton7, L. Geriniere8, F. Forest9, R. Gervais10, I. Monnet11, A. Madrosyk12, F. Guisier13, C. Serrand14, C. Locher Genty15, C. Decroisette16, J.B. Auliac17, T. Jeanfaivre18, H. Doubre19, D. Arpin20

Author affiliations

  • 1 Pathology, Université Paris Descartes, 75006 - Paris/FR
  • 2 Pathology, APHP, 75014 - paris/FR
  • 3 Pneumology, CH d'aix, 13616 - aix en provence/FR
  • 4 Pathology, selas cypath, 69100 - villeurbane/FR
  • 5 Pathology, CH rene Dubos, 95300 - pontoise/FR
  • 6 Pneumology, CH Sud Bretagne, 56322 - Lorient/FR
  • 7 Pahtology, CHU Charles Nicolle, 76031 - rouen/FR
  • 8 Pneumology, CHLS, 69310 - lyon/FR
  • 9 Pathology, CHU st etienne, 42270 - st etienne/FR
  • 10 Pneumology, Centre Francois Baclesse, 14076 - Caen/FR
  • 11 Pneumology, CH Intercommunal de Créteil, 94010 - Créteil/FR
  • 12 Medical Oncology, Institut paoli calmette, 13009 - marseille/FR
  • 13 Medical Oncology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 14 Pneumology, hôpital nord ouest, 69400 - villefranche sur saone/FR
  • 15 Medical Oncology, Centre hospitalier général Meaux, 77104 - Meaux/FR
  • 16 Pneumology, Le Centre Hospitalier Annecy Genevois, 74370 - Metz-Tessy/FR
  • 17 Pneumology, CH François Quesnay, 78201 - Mantes La Jolie/FR
  • 18 Pneumology, CHU zngers, 49100 - angers/FR
  • 19 Pneumology, Hopital Foch, 92151 - Suresnes/FR
  • 20 Pneumology, CH nord ouest, 69400 - villefranche sur saone/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1781


Large cell neuroendocrine carcinomas of the lung (LCNECs) are rare neoplasms with limited therapeutics options. Pathological diagnostic of LCNECs is morphologically based, may be difficult and need immunohistochemical (IHC) analysis. Immune checkpoint inhibitors targeting tumoral and immune cells interaction have changed the NSCLC treatment but few data are available on LCNECs immune environment and particularly the expression of PD-L1 on both tumors (TC) and immune infiltrating (IC) cells. The objective of the present study is to determine the expression and pattern of PD-L1 staining in a cohort of LCNECs patients.


Clinical files and tumors biopsies of patients (pts) with a LCNEC diagnosed between 01.01.2014 and 31.12.2016 were retrospectively collected (GFPC 03-2017). All histological samples were centrally reviewed by six pathologists, according to the latest WHO 2015 classification. LCNEC was confirmed and PD-L1 expression was determined both in TC and IC, using the anti-PD-L1 antibody 22C3 (kit and automat Dako). PD-L1 expression was scored on TC as the percentage of PD-L1 positive cells (0 to 100%). PD-L1 expression on IC was determined as follows: IC0: positive IC representing < 1% of the tumor surface; IC1 : positive IC representing ≥1% but <5 % of the tumor surface ; IC2 : positive IC representing ≥ 5% but <10% of the tumor surface ; and IC3 : positive IC representing >10% of the tumor surface.


86pts were initially included in the study, 28 (32%) were excluded for non-LCNEC diagnosis. Among the 58 pts with LCNEC, five (8%) had a composite LCNEC with a NSCLC component. The mean age of the population was 65 years, mainly mens (86%) and former or current heavy smokers (93%). PD-L1 was positive on TC for only 12% of the samples, while 76 % of the samples shows IC PD-L1 positive, with respectively 18 (35%) IC3, 8(14%) IC2, and 13(25%) IC1.


LCNEC display a particular PDL1 expression pattern, different from NSCLC and from SCLC and may suggest a potential effectiveness of therapeutic anti PD-L1 antibodies, this hypothesis have to be addressed in clinical trial.

Clinical trial identification

Legal entity responsible for the study



Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.